Safety of meloxicam: a global analysis of clinical trials.

Meloxicam is a new preferential cyclooxygenase-2 (COX-2) inhibitor for the treatment of rheumatic disease. This paper presents a global safety analysis of data from meloxicam clinical studies, focusing on gastrointestinal (GI) adverse events. Meloxicam 7.5 and 15 mg (n = 893 and 3282) were compared with piroxicam 20 mg (n = 906), diclofenac 100 mg slow release (n = 324) and naproxen 750-1000 mg (n = 243). With respect to all GI adverse events, meloxicam 7.5 and 15 mg were significantly better than all comparators in a pooled analysis of double-blind studies in rheumatoid arthritis (RA) and osteoarthritis (OA). When examining non-serious GI events, severe GI events, discontinuous due to GI events, dyspepsia, abdominal pain and upper GI events, both meloxicam doses were significantly better than comparator non-steroidal anti-inflammatory drugs (NSAIDs) in most cases. Where statistical significance was not demonstrated, there was generally a trend in favour of meloxicam. With respect to upper GI perforations, ulcerations and bleedings, the most serious of NSAID-associated side-effects, meloxicam was better tolerated than the comparators, reaching statistical significance for piroxicam and naproxen. Meloxicam's improved GI safety profile is likely to be due to its preferential inhibition of inducible COX-2 relative to constitutive COX-1.

[1]  Loring T. Swaim.  THE AMERICAN RHEUMATISM ASSOCIATION , 1938 .

[2]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[3]  V. D’Agati,et al.  Renal toxicity of nonsteroidal anti-inflammatory drugs. , 1987, Contributions to nephrology.

[4]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[5]  D. Graham,et al.  Dyspepsia in NSAID Users: The Size of the Problem , 1989, Journal of clinical gastroenterology.

[6]  K. Giercksky,et al.  Epidemiology of NSAID-related gastrointestinal side effects. , 1989, Scandinavian journal of gastroenterology. Supplement.

[7]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[8]  J. Fries,et al.  Identification of patients at risk for gastropathy associated with NSAID use. , 1990, The Journal of rheumatology. Supplement.

[9]  J. Fries.  NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. , 1991, The Journal of rheumatology. Supplement.

[10]  S. Gabriel,et al.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. , 1991, Annals of internal medicine.

[11]  K. Seibert,et al.  Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Dewitt,et al.  Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. , 1993, The Journal of biological chemistry.

[13]  C. Thiemermann,et al.  Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Jick,et al.  Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs , 1994, The Lancet.

[15]  D. Bateman.  NSAIDs: time to re-evaluate gut toxicity , 1994, The Lancet.

[16]  A. Swart.  Relative safety of oral non-aspirin NSAIDS , 1994 .

[17]  J. Vane.  Towards a better aspirin , 1994, Nature.